Bausch & Lomb Licenses Ophthalmic Drug From Schering AG

Preclinical compound discovered during Schering’s anti-inflammatory research does not fit into the company’s product portfolio.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet